Biologics in inflammatory bowel disease: how much progress have we made?
about
A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UCIncreased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.The complement anaphylatoxin C3a receptor (C3aR) contributes to the inflammatory response in dextran sulfate sodium (DSS)-induced colitis in mice.Risks and benefits of biologic therapy for inflammatory bowel diseases.Immunogenicity of biological agents in inflammatory bowel disease.Infliximab use in Crohn's disease.Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease.Safety of biologic therapy.Biologic targeting in the treatment of inflammatory bowel diseases.SD0006: a potent, selective and orally available inhibitor of p38 kinase.Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease.Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula.Profile of infliximab in the treatment of pediatric Crohn's disease.Treatment of Crohn's disease with certolizumab pegol.Antibody-Based Targeted Delivery of Interleukin-22 Promotes Rapid Clinical Recovery in Mice With DSS-Induced Colitis.“New drugs: Kids come first”: Children should be included in trials of new biological treatmentsNew insights into the biological therapy of Crohn’s disease
P2860
Q28248835-B04E54A4-2972-4FF6-91BA-982BF91B7427Q33541428-71445D3C-7152-438C-8A6E-FA9C57938FC5Q34701117-3C07CBAC-86EB-42F5-A51E-266095EA81D2Q35929544-6C57DCD5-8100-41D8-ADB8-21CEE638AA71Q36113933-D8E2FBD3-FB43-45A8-AEB3-5018F06BDCF3Q36150474-510F0F37-CE58-4288-AC56-7E9A236C9E5CQ36167373-1DDEB8A9-3EAC-4054-8A91-D1CCFECEC6EEQ36737339-321E11B3-458C-424C-9F7D-985B35A4CE72Q37303206-30938247-0C7A-4CB3-B2F9-EA76C0E8A5B9Q37466941-F332FF80-D8F6-431A-9425-B899B73CC427Q37680981-C17BCE7A-1079-409B-BE66-D7E2FF54061BQ39951547-7247974B-19FF-40D2-B367-FFC2B24955FFQ42844744-B93E45E3-249A-4ECF-AC74-683A09ECEB45Q49165025-85BE624A-B047-4782-A102-FF4355FDF77EQ50923712-4CC9543E-DAE7-4E7A-A866-0C9D7768B044Q51599949-481D8667-6445-4AC5-94EE-8AE760562718Q57804309-C26F60E2-EDE9-44AC-8A2C-362FBE18C5B2Q57821547-10CBA82F-F748-4741-9BE8-9B7C0442877D
P2860
Biologics in inflammatory bowel disease: how much progress have we made?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Biologics in inflammatory bowel disease: how much progress have we made?
@ast
Biologics in inflammatory bowel disease: how much progress have we made?
@en
type
label
Biologics in inflammatory bowel disease: how much progress have we made?
@ast
Biologics in inflammatory bowel disease: how much progress have we made?
@en
prefLabel
Biologics in inflammatory bowel disease: how much progress have we made?
@ast
Biologics in inflammatory bowel disease: how much progress have we made?
@en
P2860
P356
P1433
P1476
Biologics in inflammatory bowel disease: how much progress have we made?
@en
P2093
W A Faubion
W J Sandborn
P2860
P304
P356
10.1136/GUT.2003.025452
P407
P577
2004-09-01T00:00:00Z